CoChat

Capsid-specific removal of circulating antibodies to adeno-associated virus vectors

Open access
Bertin, Berangere, Veron, Philippe, Leborgne, Christian, Deschamps, Jack-Yves, Moullec, Sophie, Fromes, Yves, Collaud, Fanny, Boutin, Sylvie, Latournerie, Virginie, van Wittenberghe, Laetitia, Delache, Benoit, Le Grand, Roger, Dereuddre-Bosquet, Nathalie, Benveniste, Olivier, Moullier, Philippe, Masurier, Carole, Merten, Otto, Mingozzi, Federico · 2020 · Scientific Reports

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Neutralizing antibodies directed against adeno-associated virus (AAV) are commonly found in humans. In seropositive subjects, vector administration is not feasible as antibodies neutralize AAV vectors even at low titers. Consequently, a relatively large proportion of humans is excluded from enrollment in clinical trials and, similarly, vector redosing is not feasible because of development of high-titer antibodies following AAV vector administration. Plasmapheresis has been proposed as strategy to remove anti-AAV antibodies from the bloodstream. Although safe and relatively effective, the technology has some limitations mainly related to the nonspecific removal of all circulating IgG. Here we developed an AAV-specific plasmapheresis column which was shown to efficiently and selectively deplete anti-AAV antibodies without depleting the total immunoglobulin pool from plasma. We showed the nearly complete removal of anti-AAV antibodies from high titer purified human IgG pools and plasma samples, decreasing titers to levels that allow AAV vector administration in mice. These results provide proof-of-concept of a method for the AAV-specific depletion of neutralizing antibodies in the setting of in vivo gene transfer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-020-57893-z

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Plasmapheresis allows for AAV vector readministration in non-human primates. (a) Experimental design. Two animals received an AAV8-U7 vector intravenously at a dose of 2.5 × 1011vg/kg (Plasmapheresis and Control), 6 weeks later one animal (Plasmapheresis) was subjected to 3 cycles of plasmapheresis at a 2-day interval (arrows). Both animals and a third naïve control animal (Naïve) were then infused with an AAV8-huSEAP vector at a dose of 2.5 × 1013 vg/kg. Triangles indicate AAV vector administrations. (b) Vector genome copy number (VGCN) per diploid genome in various tissues collected at sacrifice. (c–e) Anti-AAV8 IgG (c), NAb (d), and IgM (e) levels over time. AAV in the x axis indicate the timing of AAV vector administration. Vertical dotted lines represent the timing of plasmapheresis cycles. Titers are reported as 1:x dilution.
Figure 1 Plasmapheresis allows for AAV vector readministration in non-human primates. (a) Experimental design. Two animals received an AAV8-U7 vector intravenously at a dose of 2.5 × 1011vg/kg (Plasmapheresis and Control), 6 weeks later one animal (Plasmapheresis) was subjected to 3 cycles of plasmapheresis at a 2-day interval (arrows). Both animals and a third naïve control animal (Naïve) were then infused with an AAV8-huSEAP vector at a dose of 2.5 × 1013 vg/kg. Triangles indicate AAV vector administrations. (b) Vector genome copy number (VGCN) per diploid genome in various tissues collected at sacrifice. (c–e) Anti-AAV8 IgG (c), NAb (d), and IgM (e) levels over time. AAV in the x axis indicate the timing of AAV vector administration. Vertical dotted lines represent the timing of plasmapheresis cycles. Titers are reported as 1:x dilution.CC BY · PubMed Central
Figure 2 AAV-specific column for the removal of anti-capsid IgG from plasma. (a) Diagram of the column. AAV capsid particles are grafted to the column matrix and allow for binding and removal of IgG specific to the capsid without affecting total antibody levels. (b) Anti-AAV8 IgG retention rate of IVIg and plasma at various concentrations and volumes. A flow rate of 0.1 ml/minute was used in all experiments. For the IVIg retention experiment, n = 3 runs. For 1 ml and 5 ml plasma at 1/7290 dilution, n = 5 runs; shown is average, error bars represent the standard error of the mean. (c) Effect of AAV capsid loading on anti-AAV8 IgG retention. Various amounts of AAV8 capsid were used to bind to the NHS-Sepharose matrix and retention of AAV8 IgG measured after IVIg or seropositive plasma loading. (d) Effect of flow rate on anti-AAV8 IgG retention. AAV8 IgG retention tested with 3 columns containing various amounts of AAV8 capsid at 3 different flow rates.
Figure 2 AAV-specific column for the removal of anti-capsid IgG from plasma. (a) Diagram of the column. AAV capsid particles are grafted to the column matrix and allow for binding and removal of IgG specific to the capsid without affecting total antibody levels. (b) Anti-AAV8 IgG retention rate of IVIg and plasma at various concentrations and volumes. A flow rate of 0.1 ml/minute was used in all experiments. For the IVIg retention experiment, n = 3 runs. For 1 ml and 5 ml plasma at 1/7290 dilution, n = 5 runs; shown is average, error bars represent the standard error of the mean. (c) Effect of AAV capsid loading on anti-AAV8 IgG retention. Various amounts of AAV8 capsid were used to bind to the NHS-Sepharose matrix and retention of AAV8 IgG measured after IVIg or seropositive plasma loading. (d) Effect of flow rate on anti-AAV8 IgG retention. AAV8 IgG retention tested with 3 columns containing various amounts of AAV8 capsid at 3 different flow rates.CC BY · PubMed Central
Figure 3 Binding of anti-AAV8 IgG to empty and full capsids. (a) AAV8 IgG retention following loading of 36 mg of IVIg loading onto NHS-Sepharose columns loaded with the same amount (2 × 1012 capsid particles, purified from the same AAV preparation) of empty vs. full capsids (empty AAV, n = 5 runs; full AAV, n = 8 runs). **p < 0.01 two-tailed unpaired t test. (b,c). ELISA assay to detect anti-AAV8 IgG in IVIg (b) or pooled human serum (c) at various dilutions. Plates were coated with 2 × 1010 capsid particles (cp)/ml of empty or full AAV8 capsid. (d,e). ELISA assay to detect anti-AAV8 IgG in IVIg using plates coated with either 2 × 1010 (d) or 2 × 1011 (e) cp/ml of empty or full AAV8 capsids deriving from n = 6 different preparations each. Error bars represent the standard error of the mean. Statistical analyses performed by RM two-way ANOVA, Sidak’s multiple comparisons test in panels (b,c) and ordinary two-way ANOVA, Sidak’s multiple comparisons test in panels (d,e). ****p < 0.0001; **p < 0.01.
Figure 3 Binding of anti-AAV8 IgG to empty and full capsids. (a) AAV8 IgG retention following loading of 36 mg of IVIg loading onto NHS-Sepharose columns loaded with the same amount (2 × 1012 capsid particles, purified from the same AAV preparation) of empty vs. full capsids (empty AAV, n = 5 runs; full AAV, n = 8 runs). **p < 0.01 two-tailed unpaired t test. (b,c). ELISA assay to detect anti-AAV8 IgG in IVIg (b) or pooled human serum (c) at various dilutions. Plates were coated with 2 × 1010 capsid particles (cp)/ml of empty or full AAV8 capsid. (d,e). ELISA assay to detect anti-AAV8 IgG in IVIg using plates coated with either 2 × 1010 (d) or 2 × 1011 (e) cp/ml of empty or full AAV8 capsids deriving from n = 6 different preparations each. Error bars represent the standard error of the mean. Statistical analyses performed by RM two-way ANOVA, Sidak’s multiple comparisons test in panels (b,c) and ordinary two-way ANOVA, Sidak’s multiple comparisons test in panels (d,e). ****p < 0.0001; **p < 0.01.CC BY · PubMed Central
Figure 4 Antibody retention profile of AAV8-Sepharose columns. All columns contained full AAV capsids (2 × 1012 vg/1 ml of resin) (a) Anti-AAV8 IgG (red) and total IgG (blue) levels measured by ELISA in flow through (FT) and elution (E) fractions of an AAV8-Sepharose column after loading seropositive dog plasma (5 ml). (b) Anti-AAV8 NAb profile of the same dog sample across selected fractions from FT and E. NAb titers are reported as reciprocal dilution (1:x). Starting NAb titer before column treatment was >1:10,000. (c,d) Anti-AAV8 IgG (red) and total IgG (blue) levels measured in non-human primate (c) and human (d) plasma (loading volume 5 ml).
Figure 4 Antibody retention profile of AAV8-Sepharose columns. All columns contained full AAV capsids (2 × 1012 vg/1 ml of resin) (a) Anti-AAV8 IgG (red) and total IgG (blue) levels measured by ELISA in flow through (FT) and elution (E) fractions of an AAV8-Sepharose column after loading seropositive dog plasma (5 ml). (b) Anti-AAV8 NAb profile of the same dog sample across selected fractions from FT and E. NAb titers are reported as reciprocal dilution (1:x). Starting NAb titer before column treatment was >1:10,000. (c,d) Anti-AAV8 IgG (red) and total IgG (blue) levels measured in non-human primate (c) and human (d) plasma (loading volume 5 ml).CC BY · PubMed Central
Figure 5 Antibody retention profile of a protein A column. Anti-AAV8 IgG (red) and total IgG (blue) levels measured by ELISA in flow through (FT) and elution (E) fractions of a protein A column after loading seropositive dog plasma (5 ml).
Figure 5 Antibody retention profile of a protein A column. Anti-AAV8 IgG (red) and total IgG (blue) levels measured by ELISA in flow through (FT) and elution (E) fractions of a protein A column after loading seropositive dog plasma (5 ml).CC BY · PubMed Central
Figure 6 In vivo testing of removal of anti-capsid antibodies with the AAV8-Sepharose column. (a) Experimental design. A seropositive sample from a dog previously dosed with an AAV8 vector and displaying a titer of 1:1000 was subjected to column-based depletion of anti-AAV8 antibodies. Untouched plasma (Plasma), flow through (FT), elution (E) or PBS as control (PBS) were delivered to C57BL/6 mice (100 ul/mouse, n = 5/6 per treatment group) on day −1. On day 0 5 × 1010 vg/mouse of AAV8-hF.IX vector were delivered intravenously. Plasma levels of hF.IX were measured at day 14 and vector genome copy number (VGCN) were measured in liver at day 28. (b) Anti-AAV8 NAb profile of samples delivered to mice on day -1. (c) hF.IX plasma levels in mice at day 14 post vector administration. (d) VGCN per diploid genome in liver of mice at sacrifice. Results in (c,d) are shown as average, error bars represent the standard error of the mean. **p < 0.01; ***p < 0.001 one-way ANOVA.
Figure 6 In vivo testing of removal of anti-capsid antibodies with the AAV8-Sepharose column. (a) Experimental design. A seropositive sample from a dog previously dosed with an AAV8 vector and displaying a titer of 1:1000 was subjected to column-based depletion of anti-AAV8 antibodies. Untouched plasma (Plasma), flow through (FT), elution (E) or PBS as control (PBS) were delivered to C57BL/6 mice (100 ul/mouse, n = 5/6 per treatment group) on day −1. On day 0 5 × 1010 vg/mouse of AAV8-hF.IX vector were delivered intravenously. Plasma levels of hF.IX were measured at day 14 and vector genome copy number (VGCN) were measured in liver at day 28. (b) Anti-AAV8 NAb profile of samples delivered to mice on day -1. (c) hF.IX plasma levels in mice at day 14 post vector administration. (d) VGCN per diploid genome in liver of mice at sacrifice. Results in (c,d) are shown as average, error bars represent the standard error of the mean. **p < 0.01; ***p < 0.001 one-way ANOVA.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 100

Metadata

Authors
Bertin, B., Veron, P., Leborgne, C., Deschamps, J.-Y., Moullec, S., Fromes, Y., Collaud, F., Boutin, S., Latournerie, V., van Wittenberghe, L., Delache, B., Le Grand, R., Dereuddre-Bosquet, N., Benveniste, O., Moullier, P., Masurier, C., Merten, O., & Mingozzi, F.
Affiliations
  • Inserm (FR)
  • Oniris (FR)
Corresponding author
Mingozzi, Federico
Venue
Scientific Reports
Published
2020-01-21
Volume
10
Issue
1
Pages
864-864
ISSN
2045-2322 (ISSN-L)
OpenAlex
W3002082131
Cited by
100
References
51
Citations by year
2026: 7 · 2025: 9 · 2024: 12 · 2023: 19 · 2022: 24 · 2021: 20 · 2020: 9
FWCI
10.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Genethon
  • Agence Nationale de la Recherche (ANR-10-EQPX-02-01)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
adeno-associated virus, neutralizing antibodies, plasmapheresis, antibody depletion, in vivo gene delivery, IgG, inclusion and exclusion criteria
MeSH terms
Dependovirus, Animals, Antibodies, Viral, Capsid, Genetic Vectors, Humans, Immunoglobulin G, Plasmapheresis, Gene Transfer Techniques, Mice, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Capsid-specific removal of circulating antibodies to adeno-associated virus vectors. https://app.cochat.ai/papers/10.1038/s41598-020-57893-z
The paper
Bertin, B., Veron, P., Leborgne, C., Deschamps, J.-Y., Moullec, S., Fromes, Y., Collaud, F., Boutin, S., Latournerie, V., van Wittenberghe, L., Delache, B., Le Grand, R., Dereuddre-Bosquet, N., Benveniste, O., Moullier, P., Masurier, C., Merten, O., & Mingozzi, F. (2020). Capsid-specific removal of circulating antibodies to adeno-associated virus vectors. Scientific Reports. https://doi.org/10.1038/s41598-020-57893-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.